Growth fraction in human brain tumors defined by the monoclonal antibody Ki-67

F. Giangaspero, C. Doglioni, M. T. Rivano, S. Pileri, J. Gerdes, H. Stein

Research output: Contribution to journalArticlepeer-review


The monoclonal antibody Ki-67, which reacts with cells in the active part of the cell cycle, was used to evaluate immunocytochemically the growth fraction in 22 primary brain neoplasms. The percentage of labelled cells reflected the histological grade of malignancy of each neoplasms. High percentage of Ki-67-positive cells were observed in one choroid plexus carcinoma (60%), one primary melanoma of meninges (40%), three medulloblastomas (40%-50%), one anaplastic astrocytoma and six glioblastomas (10%-40%). One ependymoma had 7% positive cells. Rare positive cells (1%) were present in one pilocytic astrocytoma and one ganglioglioma. Except one negative case, the meningiomas (five cases) had values of positivity ranging from 1% to 6%. Two acoustic schwannomas were negative. These results suggest that immunocytochemical staining with the Ki-67 may be a useful method for measuring the growth fraction in brain neoplasms.

Original languageEnglish
Pages (from-to)179-182
Number of pages4
JournalActa Neuropathologica
Issue number2
Publication statusPublished - Jun 1987


  • Brain neoplasm
  • Cell kinetics
  • Immunocytochemistry
  • Ki-67
  • Monoclonal antibody

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pathology and Forensic Medicine
  • Clinical Neurology


Dive into the research topics of 'Growth fraction in human brain tumors defined by the monoclonal antibody Ki-67'. Together they form a unique fingerprint.

Cite this